Loss of somatostatin-like immunoreactivity in the frontal cortex of Alzheimer patients carrying the apolipoprotein epsilon 4 allele

Neuroscience Letters

Volumn 255, Issue 1, 1998, Pages 21-24

  Grouselle, Dominique ^a   Winsky Sommerer, Raphaëlle ^a   David, Jean Philippe ^b   Delacourte, André ^a   Dournaud, Pascal ^a   Epelbaum, Jacques ^a  

^a INSERM   (France)

^b Hôpitaux Universitaires Henri Mondor   (France)

Author keywords

Alzheimer's disease; Apolipoprotein E4; Cortistatin; Frontal cortex; Somatostatin

Indexed keywords

APOLIPOPROTEIN E4; SOMATOSTATIN;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; FEMALE; FRONTAL CORTEX; GENE LOCUS; GENOTYPE; HUMAN; IMMUNOREACTIVITY; INTERNEURON; MALE; OLIVARY NUCLEUS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PROCESSING;

AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; CADAVER; FRONTAL LOBE; HUMANS; OSMOLAR CONCENTRATION; RADIOIMMUNOASSAY; SOMATOSTATIN;

EID: 0032500857     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(98)00698-3     Document Type: Article

References (27)

1. Basun H., Grut M., Winblad B., Lannfelt L. Apolipoprotein epsilon 4 allele and disease progression in patients with late-onset Alzheimer's disease. Neurosci. Lett. 183:1995;32-34.
2. Bennett C., Crawford F., Osborne A., Diaz P., Hoyne J., Lopez R., Roques P., Duara R., Rossor M., Mullan M. Evidence that the apoE locus influence rate of disease progression in late-onset familial Alzheimer's disease but is not causative. Am. J. Med. Genet. 60:1995;1-6.
3. Buee-Scherrer V., Condamines O., Mourton-Gilles C., Jakes R., Goedert M., Pau B., Delacourte A. AD2, a phosphorylation-dependent monoclonal antibody directed against tau proteins found in Alzheimer's disease. Brain Res. Mol. Brain Res. 39:1996;79-88.
4. Cervera-Pierrot P., Hirsch E., Javoy-Agid F., Ransmayr G., Hauw J., Agid Y. Hippocampal and parahippocampal somatostatin 28 and neuropeptide Y containing neurons in Alzheimer's disease. Dementia. 3:1992;282-298.
5. Corder E., Saunders A., Strittmatter W., Schmechel D., Gaskell P., Small G., Roses A., Haines J., Pericak-Vance M. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 261:1993;921-923.
6. Davies P., Katzmann R., Terry R.D. Reduced somatostatin-like-immunoreactivity in cerebral cortex from cases of Alzheimer's disease and Alzheimer senile dementia. Nature. 288:1980;279-280.
7. Dawbarn D., Rossor M., Mountjoy C., Roth M., Emson P. Decreased somatostatin immunoreactivity but not neuropeptide Y immunoreactivity in cerebral cortex in senile dementia of the Alzheimer type. Neurosci. Lett. 70:1986;154-159.
8. De Lecea L., Criado J.R., Prospero-Garcia O., Gautvik K.M., Scweitzer P., Danielson P., Dunlop C., Siggins G., Henriksen S., Sutcliffe J. A cortical neuropeptide with neuronal depressant and sleep modulating properties. Nature. 381:1996;242-245.
9. Dournaud P., Cervera-Pierot P., Hirsch E., Javoy-Agid F., Kordon C., Agid Y., Epelbaum J. Somatostatin messenger RNA-containing neurons in Alzheimer's disease: an in situ hybridization study in hippocampus, parahippocampal cortex and frontal cortex. Neuroscience. 61:1994;755-764.
10. Dournaud P., Delaere P., Hauw J.J., Epelbaum J. Differential correlation between neurochemical deficits, neuropathology and cognitive status in Alzheimer's disease. Neurobiol. Aging. 16:1995;817-823.
11. Fukusumi S., Kitada S., Takekawa S., Kisawa H., Sakamoto J., Miyamoto M., Hinuma S., Kitano K., Fujino M. Identification and characterization of a novel human cortistatin-like peptide. Biochem. Biophys. Res. Commun. 232:1997;157-163.
12. Hyman B., West H., Rebeck G., Buldyrev S., Mantegna R., Uklega M., Havlin S., Stanley H. Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome). Proc. Natl. Acad. Sci. USA. 92:1995;3586-3590.
13. Locke P., Connealy P., Tanzi R., Gusella J., Haines J. Apolipoprotein-E4 allele and Alzheimer's disease-examination of allelic association and effect of age at onset in both early-onset and late-onset cases. Genet. Epidemiol. 12:1995;83-92.
14. Mahley R. Apolipoprotein E: cholesterol transprotein with expanding role in cell biology. Science. 240:1988;622-629.
15. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Vogel F.S., Hughes J.P., van Belle G., Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 41:1991;479-486.
16. Nieuwenhuys, R., Voogd, J. and Van Huijzen, C., The Human Central Nervous System. A Synopsis and Atlas, 3rd edn. (revised), Springer-Verlag, Berlin, 1988.
17. Pierotti A., Harmar A., Simpson J., Yates C. High molecular weight forms of somatostatin are reduced in Alzheimer's disease and Down's syndrome. Neurosci. Lett. 63:1985;141-146.
18. Poirier J. Apolipoprotein E in animal models of brain injury and in Alzheimer's disease. Trends Neurosci. 12:1994;525-530.
19. Poirier J., Davignon J., Bouthillier D., Kogan S., Bertrand P., Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet. 342:1993;697-699.
20. Poirier J., Delisle M., Quirion R., Aubert I., Farlow M., Lahrid D., Hui S., Bertrand P., Nalbantogu J., Gilfix B.M. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc. Natl. Acad. Sci. USA. 92:1995;12260-12264.
21. Rebeck G., Reiter J., Strickland D., Hyman B. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron. 11:1993;575-580.
22. Rorstad O., Epelbaum J., Brazeau P., Martin J. Chromatographic and biological properties of immunoreactive somatostatin in hypothalamic and extrahypothalamic brain regions of the rat. Endocrinology. 105:1979;1083-1092.
23. Sergeant N., David J.P., Goedert M., Jakes R., Vermersch P., Buee L., Lefranc D., Wattez A., Delacourte A. Two-dimensional characterization of paired helical filament-tau from Alzheimer's disease: demonstration of an additional 74-kDa component and age-related biochemical modifications. J. Neurochem. 69:1997;834-844.
24. Soininen H., Kosunen O., Helisalmi S., Mannermaa A., Paljarvi L., Talasniemi S., Ryynanen M., Riekinnen P. A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein epsilon 4 allele. Neurosci. Lett. 187:1995;79-82.
25. Strittmatter M., Cramer H., Reuner C., Strubel D., Hamann G., Schimrigk K. Molecular forms of somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with senile dementia of the Alzheimer type. Biol. Psychiatry. 41:1997;1124-1130.
26. Svensson A., Warpman U., Hellstrom-Lindhal E., Bogdanovic N., Lannfelt L., Nordberg A. Nicotinic receptors, muscarinic receptors and cholineacetyltransferase activity in the temporal cortex of alzheimer patients with differing apolipoprotein E genotypes. Neurosci. Lett. 232:1997;37-40.
27. Zhang Z., Lappi D., Wrenn C., Milner T., Wiley R. Selective lesions of the cholinergic basal forebrain cause a loss of cortical neuropeptide Y and somatostatin neurons. Brain Res. 800:1998;198-206.